Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05668351 · ClinicalTrials.gov registry record · NA
Stereotactic Ablative Radiation Therapy for Prostate Cancer
A NA study of Prostate Cancer, sponsored by Medical University of South Carolina.
- Active
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05668351: Active NA study of Prostate Cancer, sponsored by Medical University of South Carolina.
NCT05668351 is a NA study of Prostate Cancer that is active but no longer recruiting, run by Medical University of South Carolina. The registered enrollment target is 42 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05668351, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by Medical University of South Carolina.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of the rectum and pudendal arteries (SUPR-SABR). This study tests the hypothesis that genitourinary (GU) and gastrointestinal (GI) toxicity rates following SUPR-SABR are comparable to (or possibly lower than) historical GU and GI toxicity rates following standard SABR (stSABR) with 36.25 Gy in the treatment of low- and intermediate-risk prostate cancer.
Primary Outcome
EPIC score at 12 months post intervention will be compared with pre-intervention scores. Score scale is 0 to 100 with lower scores indicating more severe symptoms.
Conditions Studied
Interventions
- RADIATION SUPR-SABR treatment
Study Locations (1)
South Carolina
- Medical University of South Carolina Hollings Cancer Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-05-12 |
| Est. Completion | 2028-01-15 |
| Phase | NA |
What the registry record for NCT05668351 still lists
NCT05668351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which SUPR-SABR treatment is the first listed.
NCT05668351 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT05668351 about?
NCT05668351 is a clinical study titled "Stereotactic Ablative Radiation Therapy for Prostate Cancer". This single arm trial will investigate a novel way to plan and deliver SABR for prostate cancer. Prostate-directed SABR will be high-dose SABR (40 Gy in 5 fractions) with central sparing of the urethra and peripheral sparing of the rectum and pudendal arteries (SUPR-SABR). This study tests the hypot...
What is the current status of trial NCT05668351?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 42 participants. The study started on 2023-05-12. Estimated completion is 2028-01-15.
What conditions does trial NCT05668351 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05668351?
The interventions under investigation include: SUPR-SABR treatment (RADIATION).
Who is sponsoring clinical trial NCT05668351?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05668351 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05668351's enrollment target sits among peer trials
42 520th of 735 higher than 212 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI